Cargando…
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies
Autores principales: | Jones, Trace M., Espitia, Claudia, Wang, Wei, Nawrocki, Steffan T., Carew, Jennifer S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842502/ https://www.ncbi.nlm.nih.gov/pubmed/31706349 http://dx.doi.org/10.1186/s40880-019-0418-0 |
Ejemplares similares
-
Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy
por: Jones, Trace M., et al.
Publicado: (2020) -
Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism
por: Jones, Trace M., et al.
Publicado: (2022) -
Targeting NEDDylation is a Novel Strategy to Attenuate Cisplatin-induced Nephrotoxicity
por: Jones, Trace M., et al.
Publicado: (2023) -
Targeting NEDDylation as a Novel Approach to Improve the Treatment of Head and Neck Cancer
por: Jones, Trace M., et al.
Publicado: (2021) -
Autophagy: New Insights into Its Roles in Cancer Progression and Drug Resistance
por: Nawrocki, Steffan T., et al.
Publicado: (2020)